Olfactory Dysfunction in the COVID-19 Outbreak

Izquierdo-Dominguez A1,2,3,*, Rojas-Lechuga MJ4,5,6, Mullol J4,5,6,**, Alobid I2,4,5,6,*,**

1Allergy Department, Consorci Sanitari de Terrassa, Barcelona, Spain
2Unidad Alergo Rino, Centro Médico Teknon, Barcelona, Spain
3Allergy Department, Clínica Diagonal, Barcelona, Spain
4Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic Barcelona, CIBERES, Universitat de Barcelona, Barcelona, Spain
5Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, Barcelona, Spain
6CIBER of Respiratory Diseases (CIBERES), Barcelona, Spain
*These authors contributed as corresponding authors.
**These authors share senior author responsibilities.

Abstract

The first cases of coronavirus 2019 disease (COVID-19) occurred in Wuhan, China, and the disease rapidly became a public health emergency of international proportions. COVID-19 can cause mild-to-severe acute respiratory syndrome (SARS) and is caused by the SARS-CoV-2 coronavirus. The clinical manifestations of COVID-19 include fever, dry cough, fatigue, sputum production, shortness of breath, sore throat, and headache. We performed this narrative review to analyze the current literature on postviral olfactory dysfunction related to the SARS-CoV-2 pandemic. Since the initial anecdotal reports from China, increasingly frequent international reports on COVID-19 indicate that 5% to 85% of affected patients lose their sense of smell, thus highlighting the very heterogeneous nature of the literature in this area. Therefore, we advise home isolation measures and/or social distancing, as well as tests to detect SARS-CoV-2 when possible, in patients with sudden and severe loss of smell who cannot be promptly evaluated.


Resumen

Los primeros casos de la enfermedad por coronavirus 2019 (COVID-19) ocurrieron en Wuhan, China, y se propagaron rápidamente para convertirse en una emergencia de salud pública y de preocupación internacional. La enfermedad puede manifestarse desde una forma leve a un síndrome respiratorio agudo grave (SARS) y es causada por el coronavirus SARS-CoV-2. Las manifestaciones clínicas de COVID-19 incluyen fiebre, tos seca, fatiga, expectoración, dificultad respiratoria, odinofagia y cefalea. El objetivo de este estudio es revisar la literatura actual sobre la disfunción olfatoria (DO) posviral en lo que respecta a la pandemia de SARS-CoV-2. Se han publicado un creciente número de estudios a nivel mundial desde los casos anecdóticos iniciales en China, en los que se ha demostrado una prevalencia variable de pérdida de olfato en pacientes COVID-19 que va desde un 5 a un 85%. Hasta la fecha, la literatura es ampliamente heterogénea respecto a la pérdida de olfato, por lo que podemos advertir y recomendar a aquellos pacientes con pérdida del olfato súbita y grave que no puedan ser evaluados rápidamente, seguir medidas de aislamiento domiciliario y/o distanciamiento interpersonal, así como realizar pruebas de diagnóstico para el SARS-CoV-2 cuando sea posible.

Introduction

The respiratory symptoms of coronavirus disease 19 (COVID-19), which is caused by the coronavirus SARS-CoV-2, are extremely heterogeneous, ranging from minimal to severe involvement that can progress rapidly to hypoxia and severe acute respiratory distress. The disease is very contagious and may be fatal. It is of the utmost importance to provide an early diagnosis focusing on alarming symptoms and thus avoid the spread of the virus. Sudden and severe olfactory dysfunction (OD), in the absence of other respiratory symptoms should alert physicians to COVID-19 infection.

The present narrative review aims to update current knowledge on the anatomy and physiology of olfactory pathways and to provide more details on the etiology of smell disorders and smell tests. We also discuss the role of OD as a diagnostic criterion and possible treatment in the context of the COVID-19 outbreak.

Anatomy and Physiology of Smell

Human sensory processes (sight, hearing, perhaps even taste and touch) are mostly well understood; however, we still do not fully understand smell, which remains an elusive sense. In fact, scientists have not been able to explain how the human body’s odor can act as a scented fingerprint. Researchers from various fields are coming together to solve the mysteries of olfaction.

The perception of flavor is perhaps the most multisensory of our everyday experiences. Flavor involves a combination of gustatory and olfactory stimuli, with the interaction of other sensory modalities, such as trigeminal perception, sight, and hearing [1].

The perception of odor is based on orthonasal smell, which is the result of sniffing (eg, the aroma of food or the bouquet of wine), and retronasal smell, which is located within the oropharynx and results from airflow via the nasopharynx during swallowing or nasal exhalation. Apart from noticeable deficiencies in detection based on chemical gustometry (sweet, sour/acidic, bitter, salty, and savory/umami), “taste” disorders most commonly reflect inadequate stimulation of the olfactory receptors in the retronasal route [2].

The human olfactory neuroepithelium constitutes 1.25% of the nasal mucosa and covers an 8- to 10-cm² area composed of the cribriform plate, the upper part of the nasal septum, and the middle/upper turbinates (Figure 1). About 10 million of the dendrites of olfactory receptor neurons in the olfactory bulb project to the mucosa. The odorants reaching the olfactory epithelium dissolve in the mucus layer and bind/activate olfactory receptors through a complex interaction often requiring odorant-binding proteins. One odor is capable of activating multiple receptor types to varying degrees [3].

Olfactory sensory neurons transduce the chemical message into nerve impulse emission frequencies and send them to the olfactory glomeruli. Olfactory information is processed and integrated into the olfactory bulb. The axons of the olfactory bulb mitral cells successively cross the olfactory peduncle and olfactory tract before projecting onto the primary olfactory cortex. The information processed in the piriform cortex then projects to various brain areas: the orbitofrontal cortex, amygdala, hypothalamus, insula, entorhinal cortex, and hippocampus [4,5]. In humans, approximately 350 functional odorant genes encode specific protein receptors that interact with their own subset of chemicals or substances, leading to the complex mechanism of smell identification [6].

Furthermore, it is very important to know that neither the olfactory sensory neurons nor the olfactory bulb neurons express specific genes, which are instead expressed in support cells, stem cells, and perivascular cells. These findings suggest that infection of nonneuronal cells leads to anosmia and related disturbances in odor perception in patients [7,8].

Etiology of the Loss of Smell

OD can be classified as either quantitative, where the ability to recognize changes in the strength of an odor is altered, or qualitative, where the ability to recognize differences in the quality of an odor is altered. Normal olfactory function is termed normosmia; quantitative disorders are classified as hyposmia (decrease in smell) and anosmia (total lack of smell) [9,10]. Physiologically, our perception of smell changes with age, and while our ability to detect smells increases up to and peaks in the fourth decade of life, recognition and identification of smells decline significantly after the sixth decade [11].

OD plays an important role in daily living by influencing food selection and nutrient intake, enjoyment of food, socialization, overall quality of life, and detection of safety hazards from food poisoning and toxic agents [9]. Several studies have shown that olfactory impairment can affect quality of life and may lead to depression [12]. Therefore, any improvement in our sense of smell can be considered a potential antidepressant [13].

Many disease states are associated with OD, including congenital causes, postinfectious disorders, sinonasal diseases, traumatic brain injuries, and neurodegenerative disorders. We can make a series of specific observations as follows:
COVID-19 and Olfactory Dysfunction

Several techniques and tools are available to explore olfactory capacity, each with advantages and disadvantages. It is important to note that of all these methods (mainly subjective reporting via a visual analog scale and psychophysical, neurophysiological, and neuroimaging techniques) are complementary because they do not measure the same olfactory parameters, functions, or processes. Psychophysical testing by a trained specialist to identify and discriminate between odors and set cut-off points is highly recommended for detection of the severity of OD and to follow up on the progression/reversal of the loss of smell (Table 1).

In the research setting, combined psychophysical and electrophysiological tests have been developed to quantify olfactory ability with functional magnetic resonance imaging [29] and electro-olfactogram [30]. The limitations of these tests are that they cannot discriminate reliably between the causes of OD and provide no information about the site of lesions.

COVID Pandemic

During the past 2 decades, we have experienced 2 fatal coronavirus outbreaks: severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012. COVID-19 has swept across the world, creating a pandemic that has led to more than 2 million cases diagnosed (2,471,136 as April 22, 2020) and almost 170,000 deaths [31].

Table 1. List of Validated Subjective Olfactory Diagnosis Tests

<table>
<thead>
<tr>
<th>Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Pennsylvania Smell Identification Test (UPSIT)</td>
</tr>
<tr>
<td>Connecticut Chemosensory Clinical Research Center Test (CCCRC)</td>
</tr>
<tr>
<td>Smell Diskettes Olfaction Test (SDT)</td>
</tr>
<tr>
<td>Odorant confusion matrix (OCM)</td>
</tr>
<tr>
<td>Dutch odor identification test (GITU)</td>
</tr>
<tr>
<td>YN-odour Identification Test (YN-OIT)</td>
</tr>
<tr>
<td>T&amp;T Olfactometer</td>
</tr>
<tr>
<td>San Diego Odor Identification Test (SDOIT)</td>
</tr>
<tr>
<td>Cross-Cultural Smell Identification Test (CC-SIT)</td>
</tr>
<tr>
<td>Combined olfactory test (COT)</td>
</tr>
<tr>
<td>Sniffin’ Sticks</td>
</tr>
<tr>
<td>Candy Smell Test (CST)</td>
</tr>
<tr>
<td>Alcohol Sniff Test (AST)</td>
</tr>
<tr>
<td>Culturally adjusted UPSIT (CA-UPSIT)</td>
</tr>
<tr>
<td>Kremer smell test (KST)</td>
</tr>
<tr>
<td>Scandinavian Odor-Identification Test (SOIT)</td>
</tr>
<tr>
<td>Pocket Smell Test (PST)</td>
</tr>
<tr>
<td>Eloit and Trotier Olfactory Test (ETOT)</td>
</tr>
<tr>
<td>Four-minute odour identification test</td>
</tr>
<tr>
<td>Barcelona Smell Test (BAST-24)</td>
</tr>
<tr>
<td>Nez du Vin smell test</td>
</tr>
<tr>
<td>Paediatric Barcelona Olfactory Test-6 (pBOT-6)</td>
</tr>
<tr>
<td>Universal Sniff Test (U-sniff), for children</td>
</tr>
<tr>
<td>Visual analog scale (VAS, 0-10 cm) for loss of smell or taste</td>
</tr>
</tbody>
</table>

© 2020 Esmon Publicidad
Transmission is thought to occur mainly from the spread of large droplets that carry virus particles. However, under certain circumstances, such as coughing, the particles can become aerosolized or airborne, thus increasing the risk of spread. The virus may also be transmitted via body fluids, direct contact, and possible fecal-oral contact [32].

Transmission is mainly by symptomatic patients. However, a larger incubation period (which can last longer than 14 days) and asymptomatic shedding can exacerbate the infectivity of the virus, resulting in a large number of carriers [33]. The combination of high transmissibility and absence of symptoms contributes to rapid spread [30-36].

Given that COVID-19 is a newly emerging infectious disease, it is critical to understand and identify the key clinical characteristics of affected patients in order to improve early detection, isolate infected individuals, and minimize the spread of the disease. Based on a recent meta-analysis (38 studies involving 3062 COVID-19 patients in China), the most common symptoms were fever, fatigue, cough, dyspnea, expectoration, and, less often, rhinorrhea or sore throat. A relatively small percentage of patients were asymptomatic (11%) [33]. Common laboratory findings include lymphocytopenia and increased values of C-reactive protein, lactate dehydrogenase, D-dimer, and erythrocyte sedimentation rate. Bilateral lung involvement has been shown to be common on chest X-ray and chest computed tomography scans [32,37]. SARS-CoV-2 infection is currently diagnosed using the reverse transcription polymerase chain reaction (RT-PCR) assay to determine nucleic acid sequence homology in nasopharyngeal or throat swabs [38].

Symptomatic infection (susceptibility) and outcome (fatality) are closely associated with age. Compared with persons aged 30-59 years, those aged below 30 and above 59 years were 0.6 and 5.1 times more likely to die after developing symptoms, revealing that the risks of symptomatic infection increased with age (e.g., ~4% per year among adults aged 30-60 years) [39]. Clinical outcomes were poorer in the case of comorbidities, such as circulatory diseases including hypertension, coronary heart disease, and or diabetes [40].

**COVID 19 and Olfactory Dysfunction**

Olfactory dysfunction is well documented in viral infections. Many viruses may lead to OD through an inflammatory reaction of the nasal mucosa and subsequent development of rhinorrhea. The main causal agents are rhinovirus, parainfluenza virus, Epstein-Barr virus, and some coronaviruses. Spontaneous improvement rates after upper respiratory infection stand at 35%-67%. Follow-up of postviral olfactory loss revealed that over 80% of patients reported subjective recovery after 1 year [41]. The exact pathophysiology of postviral OD is not well understood. No specific upper respiratory symptoms allow COVID-19 to be reliably distinguished from other types of viral respiratory infections.

The respiratory epithelium is the primary site of SARS-CoV-2 attachment and infection, as is the case in many other respiratory viruses. Therefore, it is not surprising that COVID-19 affects the olfactory neuroepithelium, with an impact on smell and flavor [42]. Our team recently demonstrated that 2 out of 3 patients with the common cold or postviral acute rhinosinusitis have impaired smell, which is associated with disease severity [16].

In January 2020, angiotensin-converting enzyme 2 (ACE2) was identified as the functional receptor for SARS-CoV-2. ACE2 is present in multiple human organs, including the CNS and skeletal muscles. The expression and distribution of ACE2 remind us that SARS-CoV-2 can cause neurologic manifestations through direct or indirect mechanisms. Autopsy results of patients with COVID-19 showed that the brain tissue was hyperemic and edematous and that some neurons were degenerated [43].

Neurologic injury has been confirmed in infection by other coronaviruses, such as SARS-CoV and MERS-CoV. Researchers detected SARS-CoV-2 nucleic acid in the cerebrospinal fluid of patients and also in their brain tissue on autopsy. The virus can enter the CNS through a hematogenous or retrograde neuronal route [44] (Figure 2). Previous studies have shown the ability of SARS-CoV to cause neuronal death in mice by invading the brain via the nose close to the olfactory epithelium [45].

Since the initial anecdotal reports from China, an increasing number of international reports of COVID-19 patients report loss of smell in 5% to 85% of patients (Table 2). A study from Iran based on online surveys showed a significant increase in new-onset anosmia since the COVID-19 outbreak [42]. Researchers found a strong correlation between the number of self-reported anosmia/hyposmia cases and COVID-19 cases. A subsequent survey in confirmed COVID-19 patients reported an 87% prevalence of olfactory impairment [42].

Vaira et al [46] studied 320 COVID-19 patients and found anosmia in 19.4%, although they did not report the method used to determine how loss of smell was measured.

A study from China reported that only 5.1% and 5.6% of hospitalized patients complained, respectively, of loss of smell and loss of taste [44]. The authors described 3 categories of neurological manifestations: CNS manifestations (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure), peripheral nervous system manifestations through direct or indirect mechanisms, and visceral manifestations (e.g., gastrointestinal disorder) [47].

**Figure 2.** Potential mechanism of induced neurodegenerative effects of SARS-CoV-2 coronavirus in human olfactory pathways. OB indicates olfactory bulb; ONE, olfactory neuroepithelium.
manifestations (taste impairment, smell impairment, vision impairment, and nerve pain), and skeletal muscle injury. However, the data were retrospectively collected from medical files. Therefore, the real prevalence may have been underestimated, because these symptoms might not be spontaneously reported if not searched for.

A study from the United Kingdom including 579 COVID-19–positive and 1123 COVID-19–negative patients revealed that loss of smell and taste (59.4%) is a strong predictor of having been infected by the COVID-19 virus [47]. Gane et al [48] correlated the number of diagnosed cases of COVID-19 in the United Kingdom with the increase in sudden anosmia, as reported on social media during the early days of the pandemic. Sudden complete loss of smell was subsequently reported in a patient without nasal obstruction. Sinus computed tomography and magnetic resonance imaging scans revealed bilateral inflammation of the olfactory clefts, with normal olfactory bulbs and tracts [49]. Villalba et al [50] described 2 elderly patients evaluated in the emergency department for anosmia/
olfactory assessment (smell test and nasal endoscopy), the epithelium [63]. However, in the absence of a complete cells, and replacement of sensory epithelium with respiratory of receptor cells, absent or fewer cilia on remaining receptor characterized by extensive cicatrization, decreased numbers (Table 1) [62].

been quantitatively assessed in only 1 study (University of reported subjective assessments of OD. To date, smell has assess olfaction will play a key role in corroborating patient-tests. Future studies using well-validated instruments to to administer a structured questionnaire and validated smell of the disease and emergency contingencies, it is impossible to administer a structured questionnaire and validated smell of airflow into the olfactory cleft. Alternatively, the patient could develop postviral anosmia syndrome, with direct infection and inflammation of the olfactory mucosa and neurodegeneration of the olfactory sensory neurons. Damage to the peripheral nervous system and its subsequent dysfunction, with anosmia or hyposmia, could be a relevant indicator of disease progression [66,67].

Treatment of Postviral Anosmia

The medical community is rapidly accruing information, and standards are likely to change quickly with newly reported results. We must learn from one another as the disease crosses the globe in order to integrate the lessons learned into clinical practice.

Postviral anosmia is the most common cause of OD, and while several treatments have been presented in the literature, there is no strong evidence for any pharmacologic treatment of postviral anosmia [68]. Similarly, we could address OD during the COVID-19 era as though it were postviral anosmia, taking into account that there is no specific treatment. Therefore, we should follow the same recommendations and management.

Treatment strategies depend upon the affected regions in the olfactory pathways. In cases of frank oral, nasal, or intracranial involvement, rational straightforward approaches to treatment are often available. In cases where damage to the sensory pathways is secondary to chronic inflammatory disease, trauma, viral invasion, toxic exposure, or unknown causes, the direction for therapy is more challenging [63].

Corticosteroids

Topical and systemic corticosteroids improve olfaction in patients with chronic rhinosinusitis [69]. Ethmoid tissue eosinophilia is associated with OD in nasal polyps, independently of disease severity. These results suggest a possible role for eosinophil or eosinophil-associated cytokines in loss of smell associated with chronic rhinosinusitis.

However, for OD that is not related to sinonasal disease and with no overt evidence of nasal inflammation, the exact treatment options are not well investigated. Studies testing the efficacy of therapies for postviral OD, including corticosteroids, report conflicting evidence. The benefit of corticosteroids is
less clear, but physicians still commonly use them as first-line therapy. Corticosteroids are hypothesized to improve olfactory function through their anti-inflammatory effects and regulation of the sodium–potassium-adenosine triphosphate enzyme found in olfactory receptor neurons [70]. A recent systematic review suggests using corticosteroid rinses to improve olfactory outcomes in selected patients, with weaker evidence supporting the use of oral corticosteroids. Topical corticosteroid sprays do not improve OD in this patient population and are not recommended [71]. On the other hand, reports have demonstrated that the use of corticosteroids may escalate COVID-19 infection. The systematic review and meta-analysis by Yang et al [72] concluded that corticosteroids are associated with increased lung injury, shock, and mortality in patients with COVID-19–related pneumonia. Although intranasal corticosteroids are not recommended for sudden and severe smell loss in COVID-19 patients taking these drugs for the treatment of sinusosal diseases, such as rhinitis or chronic rhinosinusitis, discontinuation is not advised [73].

**Olfactory Training**

It is well known that in patients without OD, threshold sensitivity improves as a result of exposure to odors and/or repeated testing. Clinical studies report that systematic exposure to odors or “olfactory training” may be beneficial to some persons with hyposmia or anosmia [74-76].

Damm et al [77] conducted a randomized, controlled, multicenter study and concluded that olfactory training is safe and seems particularly useful in patients who start within 12 months after the onset of OD. The patient’s condition improves with this approach, and the use of odors at higher concentrations facilitates the improvement. The authors recommend olfactory training as a first successful therapeutic regimen in patients with postviral anosmia.

**Vitamins**

Vitamin A (b-carotene or retinol) is a potential treatment for loss of smell. The initial use of vitamin A in the chemical senses was based upon the idea that a pigmented epithelium is critical for olfactory transduction. Intranasal vitamin A at a dose of 10 000 IU/d for 2 months may be useful in the treatment of postinfectious olfactory loss [78].

**Concluding Remarks and Recommendations**

Sudden and severe olfactory or taste dysfunction, in the absence of other respiratory diseases, such as allergic rhinitis, acute rhinosinusitis, or chronic rhinosinusitis, should alert physicians to COVID-19 infection. Assessing the sense of smell in these patients may help to identify patients requiring quarantine and/or early treatment. A fast-moving pandemic demands equally agile research techniques using real-time data collection. Assessing loss of smell with subjective self-reported or psychophysical tests could help the early detection of infected patients and reduce the number of carriers, thus preventing the spread of the virus. Given the heterogeneous nature of data reported in the literature since the beginning of the COVID-19 outbreak, we advise home isolation measures and/or social distancing, as well as diagnostic tests for SARS-CoV-2 when possible in patients with sudden and severe loss of smell. Olfactory training, as a treatment, may be beneficial for some patients with permanent loss of smell after COVID-19.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of Interest**

Isam Alobid has acted as a consultant for Roche, Novartis, Mylan, Menarini, and MSD. Joaquim Mullol has participated in national and international advisory boards and received speaker’s fees and funding for clinical trials and research projects from ALK, AstraZeneca, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mitsubishi-Tanabe, MSD, Mylan-MEDA Pharma, Novartis, Regeneron Pharmaceuticals, SANOFI-Genzyme, UCB Pharma, and Uriach Group.

The remaining authors declare that they have no conflicts of interest.

**References**

Olfactory Dysfunction Outbreak. medRxiv. 2020. doi: https://doi.org/10.1101/2020.03.23.20041889


Manuscript received April 26, 2020; accepted for publication May 14, 2020.

Adriana Izquierdo-Dominguez
Consorci Sanitari de Terrassa
Calle Torrebonica s/n
08227 Barcelona, Spain
E-mail: adrianaeizquierdo@hotmail.com

Isam Alobid
Hospital Clinic
Calle Villarroel 170
08035 Barcelona, Spain
E-mail: isamalobid@gmail.com